Strategic Acquisition Zimmer Biomet’s acquisition of EmCyte in March 2023 signals a broader distribution and potential cross-sell opportunities within a larger global portfolio. Leverage this integration to approach Zimmer Biomet customers with combined autologous biologics capabilities and enhanced service offerings.

Regenerative Market EmCyte operates in the growing autologous biologics and platelet-rich plasma space with FDA clearances across multiple systems. This positions the company to expand sales through clinics and surgical centers seeking established, compliant PRP and progenitor cell technologies.

Manufacturing Excellence Fort Myers headquarters with certified clean rooms and modern manufacturing enables reliable product quality and customization for customers. Emphasize value to orthopedic, cosmetic, and sports medicine providers demanding consistent device performance at point of care.

Clinical Credibility Over twenty years in device manufacturing and a track record of FDA 510(k) clearances bolster trust with hospital networks and private practices. Target enterprise accounts seeking proven solutions with regulatory backing.

Strategic Partnerships Past collaborations with Konica Minolta and ongoing educational initiatives create openings for co-marketing, training programs, and integration opportunities with imaging and ultrasound-guided therapies. Propose bundled education and device packages to clinics.